ALIPAY
20.5.2020 11:02:03 CEST | Business Wire | Press release
Alipay, the world’s leading open digital lifestyle platform operated by Ant Group, today unveiled data showing how China’s service industry is embracing the power of digital technology as it continues to recover from the impact of COVID-19 and prepare for the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005309/en/
Service providers in China have built over 800 Alipay mini programs in just two months, each with more than 10,000 monthly active users (MAU), since Alipay first announced a plan to help 40 million service providers go digital . By leveraging Alipay’s AI-driven incentive programs, service providers that consistently improve users’ experience on the platform can receive optimized user traffic.
“The service industry is at a critical juncture in its digital journey, and Alipay continues to play an important role in facilitating this transformation,” said Simon Hu, Ant Group’s Chief Executive Officer. “This pivot to digital is expected to drive significant growth for the internet sector in the next decade.”
“We are committed to opening up our platform and collaborating with our partners to support more service providers as they continue to go digital,” Simon said.
On-demand logistics services company Huolala underwent a digital transformation shortly after business plunged 93% during the COVID-19 outbreak. The Shenzhen-based company rapidly developed and deployed an Alipay mini program to make its delivery services available to users of the app.
Today, Huolala continues to improve customer experience on the platform by optimizing and adding new services to its Alipay mini program. As a result, the company’s mini program has received more optimized user traffic. Winnie Xue, Business Development Director at Huolala, said, “Alipay’s mini programs can also run seamlessly on other major platforms within the Alibaba ecosystem, such as AutoNavi and Tmall, enabling service providers like us to reach more users without incurring additional development costs.”
As a result, Huolala’s daily transactions via Alipay soared 667% from March to April, representing a year-on-year surge of 142%.
Managers of more than 1,000 scenic destinations, as well as 300 city administrators in China, have also set up Alipay mini programs so users can access services such as carpark payments and making hospital or viral test appointments, without having to installing separate apps for each service.
As of May 20, city administrators in more than 100 cities across China have also issued consumption coupons via Alipay mini programs, with 90% of the beneficiaries being SMEs, such as milk tea shops, restaurants and hair salons.
Alipay is also working with Independent Software Vendors (ISVs), enabling them to support service providers on their digital transformation journey. ISVs package Alipay’s technologies into solutions to meet the needs of specific industries and use cases, ranging from consumer retail, food-and-beverage, hotels-and-accommodations, transportation to medical services. Service providers going digital has also brought about new growth opportunities for ISVs.
Case studies of ISVs supporting service providers to go digital on Alipay
- ISV Qimaiyunshang helps catering businesses develop Alipay mini programs that enable customers to scan a QR code to order food, or wait in a virtual queue via the Alipay app. It saw a surge of 20,000 new catering business clients in the past month due to increasing demand from restaurant owners for digital services.
- Quick Ying Technology, an ISV focused on the tourism sector, supported managers of 50 scenic destinations to launch their Alipay mini programs since mid-February, and has hired an additional 30% more people to cope with the surge in clients.
About Alipay
Alipay is the world's leading open digital lifestyle platform operated by Ant Group. In 2004, Alipay launched as an escrow service to address the issue of trust between online buyers and sellers in the early days of e-commerce in China. Continuously innovating to bring mobile payment to the world, Alipay serves more than 1.2 billion users worldwide together with its global e-wallet partners as of June 30, 2019.
Alipay has evolved from a payment tool to become a one-stop digital lifestyle platform. Through an open platform strategy, it introduces service providers from sectors such as local living, public services, and financial services, to bring consumers a more comprehensive experience. Along the way, it helps merchants digitalize their operations, promoting digital transformation in the service industry.
Alipay actively shares its financial technology experience with overseas partners, in order to bring inclusive financial services to the world. Working with more than 250 overseas financial institutions, Alipay created online payment channels for buyers and sellers in more than 200 countries and regions. When Chinese people travel abroad, they can pay directly using their mobile phones, and receive dedicated local merchant services through Alipay. These services have been introduced in 56 countries and regions. Tax reimbursement via Alipay is supported in 35 countries and regions, and Alipay supports 27 different currencies. In addition, foreign tourists and foreigners living in China can also use Alipay for mobile payments in the country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005309/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
